Answers are grounded in this paper and cite their sources.
In advanced Hodgkin’s disease, optimistic results can be ascribed to conventional chemotherapy, with more than 80% complete remission. However, one subset of patients has a poor survival, with a relapse rate of over 30%. A total of 20% of patients are refractory to initial treatment while 3040% of complete responders relapse, and are cured by salvage therapy in only 2040% of cases. In summary approximately half of all patients are not cured of their disease by conventional means. Prognostic factors in advanced Hodgkin’s disease have been determined in order to identify from the start, patients with poor prognosis who would then be eligible for new, alternative therapeutic strategies. Several questions have been raised concerning the best parameters for identifying these patients. In univariate analysis, numerous adverse prognostic factors have been described and can be placed under several general headings. The first category is related to the patient: age and performance status. The second set of factors describes the extent of the disease: number of extranodal sites, subdiaphragmatic involvement with inguinal nodes, bulk of the disease. Two biological markers are related to tumor growth: serum lactate dehydrogenase (LDH) and beta-2 microglobulin. The final group of factors is related to some particularity of the disease itself, and inflammatory processes such as B symptoms, anemia, elevated sedimentation rate and low albumin level. It is likely that new markers such as serum cytokine levels or receptor expression will eventually clarify this hetero
No takes yet. Share an insight, caveat, or question.
Gisselbrecht et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: